四環醫藥(00460.HK)附屬通過“受讓+增資”方式獲深圳易美80%股權 拓展光電設備領域佈局
格隆匯3月14日丨四環醫藥(00460.HK)宣佈，近日，公司附屬北京渼顏空間生物醫藥有限公司(”渼顏空間“)與深圳易美醫學科技有限公司(”深圳易美“)及其原股東(”賣方“)訂立股權轉讓協議和增資協議，以受讓股權及增資的方式投資深圳易美，完成後，渼顏空間將持有深圳易美80%的股份權益。
深圳易美擁有準直型超聲和淺表聚焦型超聲二合一的專利技術，並通過自主研發，成為國內第一家將這項二合一專利技術成功應用在已批准上市的醫療器械上的企業。深圳易美自主研發的產品擁有發明專利2項，實用新型專利3項，外觀設計專利5項，軟件著作4項，等多項創新性設計。
聚焦型超聲技術是通過超聲換能器將電能轉化為聲能，發射聚焦超聲波，作用於靶區組織，利用超聲的熱效應、空化效應、機械效應等，進行疾病治療、醫學美容的一種無創、綠色、安全的技術方法，是非侵入性塑身技術的創新技術之一。
與微波、射頻、冷凍技術相比，超聲波具有可穿透、可聚焦、無創、無損通道以及作用於不同深度靶點等優勢，聲束向聲軸方向會聚，在一定深度形成焦點╱焦斑，有效治療深度可達50~70mm，獨特的球面輸出設計可更好的適用於平面面積較大，損傷深度較深的部位，比平面超聲適用更廣。該項技術更可拓展應用到更多場景，實現物聯網+醫療新型合作模式。
同時，深圳易美還引進全球領先的冷熱溶脂系統。該系統利用最新的RET射頻技術，刺激細胞進行摩擦、碰撞、震動等物理運動產生深源熱，升高人體基礎體温，增加基礎代謝率和免疫能力，從而促進皮下及內臟脂肪分解和代謝。該系統靶向性定位內臟脂肪溶解，無痛無創，無反彈，可實現減脂與緊緻的雙重功效，使求美者每次治療都有明顯的效果。
隨着醫美的普及，中國光電類醫美市場規模也隨之增長，根據頭豹研究院測算，光電類醫美市場規模從2016年的93.61億元增長到2019年215.01億元，CAGR達31.94%。2025年電醫美市場規模有望達到502.億元，CAGR達13.43%。
公吿稱，該次收購深圳易美將有助於集團拓展在光電設備領域的佈局，依託深圳易美現有技術平台，及其在了超聲及冷熱溶脂技術優勢，集團未來將繼續加大在創新型醫學美容醫療器械領域研發與引進的資源投入，着力打造並強化深圳易美的獨特性與創新性優勢，形成自主研發、技術注入、以及國際領先光電產品引進的多維合力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
